Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Epilepsy

    Current Location

    Search
    Epilepsy
    Show Map
    Map View
    Your Location

    Popular Searches

    By Condition

    Depression Clinical Trials

    Anxiety Clinical Trials

    Schizophrenia Clinical Trials

    ADHD Clinical Trials

    Bipolar Disorder Clinical Trials

    Multiple Sclerosis Clinical Trials

    Autism Clinical Trials

    Treatment Resistant Depression Clinical Trials

    Borderline Personality Disorder Clinical Trials

    Social Anxiety Disorder Clinical Trials

    Parkinson's Disease Clinical Trials

    Alzheimer's Disease Clinical Trials

    By Location

    Clinical Trials in California

    Clinical Trials in Florida

    Clinical Trials in Texas

    Clinical Trials in New York

    Clinical Trials in Ohio

    Clinical Trials in Illinois

    Clinical Trials in Pennsylvania

    Clinical Trials in Michigan

    Clinical Trials in North Carolina

    Clinical Trials in Massachusetts

    Clinical Trials in Missouri

    Clinical Trials in Minnesota

    Other People Viewed

    By Subject

    Top Focal Epilepsy Clinical Trials

    20 Depression Trials near High Point, NC

    154 Clinical Trials near Bradenton, FL

    Top Pancreas Cancer Clinical Trials

    Top Hyperhidrosis Clinical Trials

    Top Amblyopia Clinical Trials

    Top Amyloidosis Clinical Trials

    Top Osa Clinical Trials

    Top Cholesterol Clinical Trials

    Top Cardiovascular Clinical Trials

    Top Asd Clinical Trials

    Top Sbrt Clinical Trials

    By Trial

    MRI + iEEG for Epilepsy

    Recorded Music for Epilepsy

    Advanced MRI Techniques for Pediatric Epilepsy

    Mobile Education App for Childhood Epilepsy

    Deep Brain vs Vagus Nerve Stimulation for Epilepsy

    Lifestyle Interventions for Epilepsy

    Brain Monitoring and Stimulation Device for Epilepsy

    Brivaracetam for Absence Epilepsy

    Brain Stimulation for Epilepsy

    Cenobamate for Seizures

    Music Therapy for Epilepsy

    Stimulating Probes and Electrodes for Epilepsy

    Related Searches

    Top Fibromyalgia Clinical Trials near Tampa, FL

    AI-Powered Support for Cancer

    Lung Preservation for Lung Transplant

    Trendelenburg Positioning for Fluid Responsiveness in ICU Patients

    PET Imaging for Melanoma

    SAPIEN 3 THV for Aortic Stenosis

    Continuous Glucose Monitoring for Gestational Diabetes

    Grocery Interventions for Childhood Obesity

    Awareness Interventions for Research Participation

    Diagnostic Tests for Detecting Barrett's Esophagus

    Vaping Prevention Ads for Adolescents and Young Adults

    KRAS Vaccine + Immunotherapy for Lung Cancer

    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      78 Epilepsy Trials Near You

      Power is an online platform that helps thousands of Epilepsy patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      CVL-865 for Seizures

      Toledo, Ohio
      The purpose of this study is to assess the long-term safety and tolerability of CVL-865 as adjunctive therapy in participants with focal onset seizures.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      105 Participants Needed

      Seizure Rescue Medication for Epilepsy

      Cleveland, Ohio
      This study will be done in two phases. Using stakeholder input (community advisory board (CAB)), the study team will adapt the SMART program to incorporate education and self-management support for use of Rescue Medication (RM) to manage seizure occurrence among Persons With Epilepsy (PWE) who have repetitive seizures. Additional content/support materials, pending input stakeholder might include posters/hand-outs that present information on the use of RM in a way that is engaging and salient to PWE. It is expected that participants will be in Phase 1 for about 3 months and participate in the CAB 2 or 3 times via zoom for 60-90 minutes/meeting. The advisory board will provide input on needed refinement of an adapted version of SMART based on their individual experiences. It is anticipate the total time commitment to be no more than 6 hours over 3 months, spread out over 2-3 meetings with review of materials possible in between meetings. Phase 2: The investigators will use a 6-month prospective trial design to test engagement with and effects of SMART-RM among approximately 35 adult (≥ 18 years) PWE who have repetitive seizures.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Glaucoma, Dementia, Suicidal, Others
      Must Be Taking:Anti-epileptic

      43 Participants Needed

      ReBOOT Program for Epilepsy

      Cleveland, Ohio
      The goal of this clinical trial is to learn if new educational program prior to epilepsy surgery can either decrease the risk of cognitive decline after surgery or be a help to those patients who experience a decline after undergoing epilepsy surgery. Participants will participate in 2 individual virtual sessions and 4 virtual group sessions over the course of 5-6 weeks prior to their epilepsy surgery. They will asked to fill out online surveys and questionnaires at various times throughout the study, up to 12 months after their surgery. To see if the educational program works, researchers will compare those participating in the educational program with those that are receiving the standard epilepsy care prior to surgery.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 60

      Key Eligibility Criteria

      Disqualifiers:Cognitive Rehab, Schizophrenia, Active Psychosis, Others

      64 Participants Needed

      Cognitive Intervention for Epilepsy

      Cleveland, Ohio
      This trial tests if online group sessions led by a brain health expert can help people with epilepsy improve their thinking and memory skills. Participants will join regular sessions for a few months and then practice on their own for several more months. The goal is to see if these mental exercises can enhance daily functioning and overall brain health.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 60

      Key Eligibility Criteria

      Disqualifiers:Non-epileptic Seizures, Cognitive Rehab, Others

      170 Participants Needed

      24/7 EEG Monitoring for Temporal Lobe Epilepsy

      Cleveland, Ohio
      The 24/7 EEG™ SubQ system will be compared to simultaneously recorded video-EEG in the Epilepsy Monitoring Unit (gold standard) and to self-reported seizure log books throughout 12 weeks of outpatient EEG recording. The present study is a 12-week open-label, prospective study with a paired, comparative design for pivotal evaluation of the safety and effectiveness of the 24/7 EEGTM SubQ system in subjects with epilepsy involving the temporal lobe region . 2-5 sites in Europe Up to 10 sites in US
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Skeletal Deformities, Infection, Others
      Must Not Be Taking:Antiplatelets, Anticoagulants, NSAIDs, Chemotherapeutics

      110 Participants Needed

      RAP-219 for Partial Seizures

      Cleveland, Ohio
      This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine if RAP-219 works and is safe in patients with Refractory Focal Epilepsy.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Generalized Seizures, Status Epilepticus, Epilepsy Surgery, Others

      30 Participants Needed

      Lifestyle Interventions for Neurological Disorders

      Cleveland, Ohio
      This trial tests if a mix of healthy activities and education can help people at risk of neurological disorders. Participants will do brain exercises, yoga, music therapy, and follow a healthy diet. The goal is to see if these activities can keep their brains healthier and delay or prevent neurological issues.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:50+

      Key Eligibility Criteria

      Disqualifiers:Chronic Illness, Intensive Treatment, Pregnancy, Hearing Loss, Vision Impairment, Others

      200 Participants Needed

      Lifestyle Interventions for Epilepsy

      Cleveland, Ohio
      A prospective controlled, randomized study to examine the effects of behavioral and wellness-based interventions on seizure frequency for adult patients with medication resistant epilepsy who are still experiencing 1 or more seizures per month.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Non-epileptic Seizures, Chronic Illness, Pregnancy, Others

      1000 Participants Needed

      Fenfluramine for Dravet and Lennox-Gastaut Syndromes

      Cleveland, Ohio
      This is an international, multicenter, open-label, long-term safety study of ZX008 in subjects with Dravet syndrome, Lennox-Gastaut syndrome or epileptic encephalopathy
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:2+

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      412 Participants Needed

      NBI-827104 for Epilepsy

      Cleveland, Ohio
      The primary objective for this study is to evaluate the long-term safety and tolerability of NBI-827104 in pediatric participants with epileptic encephalopathy with continuous spike-and-wave during sleep (EECSWS).
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Age:4 - 12

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      24 Participants Needed

      BHV-7000 for Epilepsy

      Lexington, Kentucky
      The purpose of this study is to determine whether BHV-7000 is effective in the treatment of idiopathic generalized epilepsy with generalized tonic-clonic seizures and includes an additional open-label extension (OLE) phase.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2, 3

      Key Eligibility Criteria

      Disqualifiers:Status Epilepticus, Repetitive Seizures, Others
      Must Be Taking:Antiseizure Medications

      242 Participants Needed

      Soticlestat for Rare Epilepsies

      Lexington, Kentucky
      The main aim is to assess the long-term safety and tolerability of soticlestat when used along with other anti-seizure treatment. Participants will receive soticlestat twice a day. Participants will visit the study clinic every 2-6 months throughout the study. Study treatments may continue as long as the participant is receiving benefit from it.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:2 - 65

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Breastfeeding, Suicide Risk, Others
      Must Be Taking:Anti-seizure Medications

      156 Participants Needed

      SPEAC System for Seizure Monitoring

      Lexington, Kentucky
      This trial tests a device that monitors muscle activity to detect seizures in veterans with arm-involved motor seizures. The device alerts users when it detects unusual muscle movements, helping to identify seizures.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:22+

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Allergies, Homelessness, Others
      Must Be Taking:Anti-epileptic Drugs

      5 Participants Needed

      TMS vs ECT for Depression

      Lexington, Kentucky
      Electroconvulsive therapy (ECT) is one of the most efficacious treatments available for treatment-resistant depression (TRD). Although a maintenance ECT protocol exists, multiple barriers limit its use for long-term use. These barriers include procedure tolerability, cognitive side effects, financial burden, and unreliable social support to accompany patients for these treatments. On the other hand, a different modality of noninvasive neuromodulation called transcranial magnetic stimulation (TMS) can be performed in the outpatient setting and does not need anesthesia. The likelihood of cognitive adverse effects with TMS is much lower than with ECT. Our clinical question encompasses piloting a maintenance TMS regimen to maintain remission in treatment-resistant major depressive disorder. This will be a patient-preference clinical trial, with patients offered the choice to initiate maintenance TMS versus maintenance ECT after their index ECT sessions for treatment-resistant depression. There will be no randomization or placebo involved in this study.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Seizures, Neurological Disorder, Others

      30 Participants Needed

      Responsive Neurostimulation for Generalized Epilepsy

      Pittsburgh, Pennsylvania
      To demonstrate that the RNS System for thalamic stimulation is safe and effective as an adjunctive therapy for the reduction of primary generalized seizures in individuals 12 years of age or older who have drug-resistant idiopathic generalized epilepsy.
      Stay on current meds
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Active Psychosis, Major Depression, Others
      Must Be Taking:Antiseizure Medications

      100 Participants Needed

      Stimulating Probes and Electrodes for Epilepsy

      Ann Arbor, Michigan
      The goal of this project is to study how the brain reacts to a small electrical signal. Researchers will be using a novel combination of recording electrodes. The researchers will measure the brain response from these electrodes.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:22 - 75

      Key Eligibility Criteria

      Disqualifiers:Permanent Electronic Implant, Chronic Conditions, Others

      5 Participants Needed

      Epilepsy Visit Planner for Epilepsy

      Ann Arbor, Michigan
      The purpose of this project is to conduct a trial to assess whether patients that receive a tablet-based waiting room priority communication tool (the "Epilepsy Visit Planner") have improved outcomes compared to patients that do not receive the tool. The project's hypotheses are: * Patients that receive the Epilepsy Visit Planner will have improved patient-provider communication compared to the non-planner group. * Patients that receive the Epilepsy Visit Planner will have improved quality of life scores. * The Epilepsy Visit Planner will score highly on process measures of feasibility and acceptability, demonstrating suitability for future larger scale study. Additionally, there is a related survey project that is not part of the clinical trial and will not be included in this registration information.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Under 18, Non-English, Cognitive Impairment, Others
      Must Be Taking:Antiepileptics

      152 Participants Needed

      Statistical Learning for Epilepsy

      Pittsburgh, Pennsylvania
      The overarching goal of this exploratory research is to understand the dynamic and flexible nature of speech processing in the human supratemporal plane. The temporal lobe has long been established as a region of interest in the speech perception and processing literature because it contains the auditory cortex. More recently, research has localized the supratemporal plane as an area that exhibits response specificity to acoustic properties of complex auditory signals like speech. The supratemporal plane, comprised of Heschl's gyrus, the planum polare, and the planum temporale, is capable of the rapid spectrotemporal analysis required to map acoustic information to linguistic representation. Neural activity in this area, however, is rarely studied directly because it is difficult to access with non-invasive measures like scalp electroencephalography (EEG). Capitalizing on the unique opportunity to access these areas via routine clinical stereoelectroencephalography (sEEG) in a patient population, this study seeks to understand how cortical responses reflect the diagnosticity of two acoustic-phonetic dimensions of interest and how responses rapidly and flexibly adapt to changes in listening demands. Examining how neural response to voice onset time (VOT) and fundamental frequency (F0) modulates as a function of perceptual weight carried in signaling phoneme categories, and identifying how changes in listening context shift perceptual weight, will provide invaluable data that indicates how speech processing flexibly adapts to short-term acoustic patterns.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:15 - 25

      Key Eligibility Criteria

      Disqualifiers:Intellectual Disabilities, Abnormal Epileptiform Activity, Others

      25 Participants Needed

      Advanced MRI Techniques for Epilepsy

      Detroit, Michigan
      This project will test the accuracy of a novel diffusion-weighted magnetic resonance imaging (DWMRI) approach using a deep convolutional neural network (DCNN) to predict an optimal resection margin for pediatric epilepsy surgery objectively. Its primary goal is to minimize surgical risk probability (i.e., functional deficit) and maximize surgical benefit probability (i.e., seizure freedom) by precisely localizing eloquent white matter pathways in children and adolescents with drug-resistant focal epilepsy. This new imaging approach, which will acquire a DWMRI scan before pediatric epilepsy surgery in about 10 minutes without contrast administration (and also without sedation even in young children), can be readily applied to improve preoperative benefit-risk evaluation for pediatric epilepsy surgery in the future. The investigators will also study how the advanced DWMRI-DCNN connectome approach can detect complex signs of brain neuronal reorganization that help improve neurological and cognitive outcomes following pediatric epilepsy surgery. This new imaging approach could benefit targeted interventions in the future to minimize neurocognitive deficits in affected children. All enrolled subjects will undergo advanced brain MRI and neurocognitive evaluation to achieve these goals. The findings of this project will not guide any clinical decision-making or clinical intervention until the studied approach is thoroughly validated.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:3 - 19

      Key Eligibility Criteria

      Disqualifiers:Prematurity, Hemiplegia, Autism, Others

      60 Participants Needed

      Subcortical Arousal Study for Epilepsy

      Pittsburgh, Pennsylvania
      The study is a multi-site study and will be conducted at up to 11 investigative sites in the United States. The study will investigate subcortical arousal circuits in visual perception using techniques with complementary strengths based on promising initial studies.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:13+

      Key Eligibility Criteria

      Disqualifiers:Severe Vision Impairment, Cognitive Impairment, Pregnancy

      72 Participants Needed

      Why Other Patients Applied

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40

      "I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

      FF
      ADHD PatientAge: 31
      Match to a Epilepsy Trial

      NRTX-1001 Neural Cell Therapy for Epilepsy

      Detroit, Michigan
      This trial tests if injecting special brain cells into the brain can help patients with hard-to-treat epilepsy. The new cells release a calming chemical to reduce seizures. Patients will also take medicines to prevent their bodies from rejecting the new cells.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Neurologic Disease, Immunodeficiency, Psychiatric Disorders, Others
      Must Be Taking:ASDs

      88 Participants Needed

      Perampanel for Status Epilepticus

      Detroit, Michigan
      This trial is testing Perampanel, a drug that blocks overactive brain signals, to help patients with severe seizures that don't respond to other treatments. The study aims to see if this drug can effectively and safely control these difficult-to-treat seizures.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Hepatic Impairment, Renal Impairment, Psychiatric Illness, Others
      Must Not Be Taking:CYP3A4 Inducers, PMP

      25 Participants Needed

      STK-001 for Dravet Syndrome

      Ann Arbor, Michigan
      This trial is testing the safety of STK-001, a new treatment for Dravet syndrome. It aims to help patients by increasing a brain protein that is usually low in this condition. The study focuses on patients who have already tried this treatment in earlier studies.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:30+

      Key Eligibility Criteria

      Disqualifiers:Unstable Medical Conditions, Others
      Must Not Be Taking:Sodium Channel Blockers

      60 Participants Needed

      SIF001 for Epilepsy

      Farmington Hills, Michigan
      This is a dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of SIF001, a monoclonal antibody with the potential to treat epilespy

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Conditions, Liver Disease, Others
      Must Be Taking:Anti-seizure Medications

      72 Participants Needed

      Ellacor Micro-Coring for Wound Care

      Louisville, Kentucky
      Since its inception of being marketed in the United States in 2021, physicians have used various post procedure skin care regimen to facilitate recovery. This study aims to examine the use of three post care products in five skin care regimens
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:45 - 65

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Dermatosis, Autoimmune Conditions, Infections, Others
      Must Not Be Taking:Anticoagulants, NSAIDs, Corticosteroids, Chemotherapy

      24 Participants Needed

      VNS for Epilepsy

      Louisville, Kentucky
      Vagal nerve stimulation is a neurosurgical procedure consisting of implantation of an impulse generator battery with leads placed into the vagus nerve in the neck. This procedure was FDA approved for epilepsy in the 1990s and is commonly performed as an outpatient surgery. The mechanism of action is not well understood; however it is increasingly recognized that electrical stimulation of the vagus nerve may impact other organ systems in the body including the immune and gastrointestinal systems. Concrete characterization of the peripheral effects of VNS in human gut microbiome and immune systems will: (1) elucidate peripheral mechanism of action of chronic VNS therapy, (2) identify peripheral preoperative biomarker of VNS efficacy, and (3) create a foundation for research investigating new GM and IM-related disease indications for VNS. The primary objective of this study is to characterize the pre- and post-operative oral and gut microbiome of patients implanted with vagal nerve stimulator (VNS) for epilepsy. Secondary objectives of this study include: (1) to characterize the pre-operative and post-operative immune profile of patients undergoing VNS implantation for epilepsy, (2) to elucidate whether oral and/or gut microbiota changes are related to VNS efficacy for epilepsy and (3) identification of a biomarker predicting VNS efficacy.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:0 - 60

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Infection, Cancer, Autoimmune, Others
      Must Not Be Taking:Anticholinergics, Corticosteroids, Antiarrhythmics, Others

      30 Participants Needed

      Neurostimulation with RNS System for Epilepsy

      Grand Rapids, Michigan
      To demonstrate that the RNS System is safe and effective as an adjunctive therapy in individuals age 12 through 17 years with medically refractory partial onset epilepsy.
      Stay on current meds
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:12 - 17

      Key Eligibility Criteria

      Disqualifiers:Generalized Seizures, Active Psychosis, Major Depression, Suicidal Ideation, Others
      Must Be Taking:Anti-seizure Medications

      200 Participants Needed

      Cannabidiol Extract for Epilepsy

      Winchester, Virginia
      This prospective double blind phase II study seeks to evaluate the safety and efficacy of BRC-003, a high CBD investigational product, in the treatment of refractory PTE (Post-Traumatic Epilepsy). The research is divided into two phases: an open-label dose-finding phase (Part A) and a subsequent randomized controlled phase (Part B). This design aims to provide a thorough understanding of the investigational product's impact on seizure frequency, seizure severity, mood, anxiety, sleep, and quality of life.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:PNES, Pregnancy, Suicidal Ideation, Others
      Must Be Taking:Anti-epileptic Drugs

      50 Participants Needed

      Lacosamide for Neonatal Seizures

      Charlottesville, Virginia
      The purpose of the study is to evaluate the efficacy of lacosamide (LCM) versus an Active Comparator chosen based on standard of care (StOC) in severe and nonsevere seizure burden (defined as total minutes of electroencephalographic neonatal seizures (ENS) per hour) in neonates with seizures that are not adequately controlled with previous anti-epileptic drug (AED) treatment.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:< 28

      Key Eligibility Criteria

      Disqualifiers:Metabolic Disturbances, Prenatal Drug Use, ECG Abnormality, Others
      Must Be Taking:Phenobarbital, Levetiracetam, Midazolam

      32 Participants Needed

      NBI-921352 for Epilepsy

      Chicago, Illinois
      The objective of this study is to assess the efficacy, safety, and pharmacokinetics of NBI-921352 as adjunctive therapy for seizures in subjects with SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE).
      Stay on current meds

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:2 - 21

      Key Eligibility Criteria

      Disqualifiers:Dravet Syndrome, Head Trauma, Others
      Must Be Taking:Antiseizure Medications

      52 Participants Needed

      123

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Epilepsy clinical trials pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Epilepsy clinical trials work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Epilepsy trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Epilepsy is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Epilepsy medical study?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Epilepsy clinical trials?

      Most recently, we added Ellacor Micro-Coring for Wound Care, Zonisamide for Partial Seizures and Subcortical Arousal Study for Epilepsy to the Power online platform.

      What are the current treatments for epilepsy?

      Treatment usually starts with daily anti-seizure medicines—over 20 are available—and about two-thirds of people become seizure-free after trying one or two of them. If seizures continue, specialists can offer individualized next steps such as surgery to remove the seizure focus, implantable stimulators that “pace” the nerves or brain (VNS, RNS, deep-brain stimulation), dietary therapy like the ketogenic or modified Atkins diet, or newer drugs including purified cannabidiol. The best plan depends on seizure type, age, other health issues and personal preferences, so care is built in partnership with an epilepsy team.

      Are you born with epilepsy or does it develop?

      Epilepsy can start two ways: you might be born with an underlying change in the brain — for example a genetic mutation or a problem that occurred during pregnancy or birth — or you can develop it later after things like a head injury, stroke, tumour or serious brain infection. Roughly one-third of cases are clearly “present from birth,” another third are due to later brain injuries or illnesses, and the rest have no obvious cause yet. In short, some people are born with the tendency, but anyone can develop epilepsy at any age if new damage or disease affects the brain’s electrical circuits.

      What is the rule of 3 for seizures?

      The ILAE’s “Rule of 3” says you can call someone seizure-free when they have gone at least three times as long as their single longest gap between seizures before the new treatment—and in any case at least 12 months—without another event. For example, if the longest break before treatment was 2 months, you need 6 months but because the rule also sets a 12-month minimum you would actually wait a full year; if the longest break was 8 months, you would need 24 months seizure-free. This personalised yard-stick helps doctors judge whether an intervention is truly working and avoids declaring success either too early (for people who naturally had long intervals) or too late (for those who seized frequently).

      What is the most serious epilepsy?

      The most immediately life-threatening situation is status epilepticus—any seizure that lasts five minutes or more or comes back before the person regains awareness; if this happens, give any prescribed rescue medicine and call emergency services because every extra minute increases the risk of brain injury or death. Over the long term, rare drug-resistant childhood syndromes such as Dravet or Lennox-Gastaut are often labeled the “most serious” because they cause daily seizures, developmental problems, and a higher risk of sudden death, so they require care at a specialized epilepsy center and a written emergency plan.

      How likely is epilepsy to go away?

      About two-thirds of children and roughly 60 % of adults who are just starting treatment become seizure-free long-term with medication alone. If seizures continue after trying two suitable drugs, the chance they stop on their own is small (under 5 % per year), but surgery or other specialised treatments can lift the seizure-free rate to about 50-70 % in people who are good candidates. Your exact odds depend on the epilepsy type, brain scans and early response to medicine, so work with your neurologist before deciding whether to stay on, stop, or escalate treatment.

      What foods prevent seizures?

      No single food can guarantee seizure prevention. What has solid evidence is a medically supervised, high-fat/very-low-carb diet (classic ketogenic or its easier cousins, the modified Atkins and low-glycaemic-index plans), which can reduce seizure frequency in about half of patients and make some seizure-free. If you’re not on one of these programs, aim for steady blood-sugar meals—plenty of non-starchy vegetables, healthy fats (olive oil, avocado, nuts, fatty fish), regular protein, and minimal added sugar—and talk with your neurologist or a dietitian before making major changes.

      What do people with epilepsy struggle with?

      People with epilepsy usually face two overlapping hurdles: the seizures themselves—figuring out triggers, preventing injuries, and coping with restrictions on driving, work, or sports—and the wider “after-shocks,” such as memory lapses, mood problems, medication side-effects, stigma, and added financial or school stress. Pinpointing which of these areas is causing the most strain and partnering with a neurologist on medication adherence, mental-health care, safety planning, and community support can greatly reduce risk and help regain independence.

      What is the difference between a seizure and an epilepsy?

      Think of a seizure as a one-time electrical “short-circuit” in the brain that can be set off by things like fever, low blood sugar, or head injury; once the trigger is gone, the risk may disappear. Epilepsy is the medical disorder in which the brain itself has an ongoing tendency to seize—diagnosed when someone has at least two unprovoked seizures (or one unprovoked seizure with a high chance of another), so the focus shifts from treating a single event to managing a long-term condition.

      What is the best epilepsy hospital in the world?

      There is no single “best” epilepsy hospital; what matters is choosing a center that holds the top accreditation for complex epilepsy care (e.g., NAEC Level 4 in the U.S. or an equivalent comprehensive program elsewhere), performs a high number of epilepsy surgeries with good outcomes, and has a multidisciplinary team and active research program. Examples that fit these benchmarks include Mayo Clinic and Cleveland Clinic (USA), King’s College Hospital/UCL in London (UK), University of Bonn (Germany), Pitié-Salpêtrière (France), Toronto Western Hospital (Canada), and Tokyo University Hospital (Japan). Ask your neurologist or local epilepsy foundation which accredited comprehensive center is closest and best suited to your insurance, travel limits, and whether you need adult or pediatric care.

      What is the best exercise for a seizure patient?

      There’s no single “best” exercise for epilepsy—the goal is to choose any activity you enjoy (brisk walking, cycling, swimming with a buddy, light weights, yoga) and do it regularly enough to meet general health targets of ~150 minutes of moderate movement plus two strength sessions weekly. Apply a safety layer: take medications on schedule, avoid personal triggers, wear a medical ID, and have supervision for water or height-related sports; studies and international guidelines show this approach improves fitness, mood, and often reduces seizures without added risk. Always confirm details with your neurologist so the plan fits your seizure pattern and other health factors.